BiomarkersDefinitions,,2001,Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,Clin Pharmacol Ther,69,89-95
HenryNL,Hayes DF,,2012,Cancer biomarkers,Mol Oncol,6,140-6
FrangogiannisNG,,2012,Biomarkers: hopes and challenges in th path from discovery to clinical practice,Transl Res,159,197-204
LeeJW,FigeysD,VasilescuJ,,2007,Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers,Adv Cancer Res,96,269-98
SmithNR,WomackC.,,2014,A matrix approach to guide IHCbased tissue biomarker development in oncology drug discovery,J Pathol,232,190-8
,2011,,Trends Pharmacol Sci,32,72-81
O'HurleyG,SjostedtE,RahmanA,LiB,KampfC,PontenF,,2014,Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers,Mol Oncol,8,783-98
AllredDC,,2010,Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer,Mod Pathol,23,S52-9
Debiec-RychterM,WasagB,StulM,De WeverI,Van OosteromA,HagemeijerA,,2004,Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity,J Pathol,202,430-8
ShahRB,ZhouM,LeBlancM,SnyderM,RubinMA,,2002,Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer,Am J Surg Pathol,26,1161-8
Duffy MJ,,2001,Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?,Clin Chem,47,624-30
Barry MJ,,1998,PSA screening for prostate cancer: the current controversy--a viewpoint,Patient Outcomes Research Team for Prostatic Diseases. Ann Oncol,9,1279-82
RifaiN,GilletteMA,CarrSA,,2006,Protein biomarker discovery and validation: the long and uncertain path to clinical utility,Nat Biotechnol,24,971-83
PaulovichAG,WhiteakerJR,HoofnagleAN,WangP.,,2008,The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline,Proteomics Clin Appl,2,1386-402
HustinxSR,CaoD,MaitraA,SatoN,MartinST,SudhirD,,2004,Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression,Cancer Biol Ther,3,1254-61
CastronovoV,WangYH,MusmeciD,DumontB,TurtoiA,,2010,Proteomic analysis of human pancreas cancers for the identification of targetable biomarkers,FASEB J,24,424-8
LogsdonCD,SimeoneDM,BinkleyC,ArumugamT,GreensonJK,GiordanoTJ,,2003,Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer,Cancer Res,63,2649-57
Iacobuzio-DonahueCA,MaitraA,OlsenM,LoweAW,van HeekNT,RostyC,,2003,Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays,Am J Pathol,162,1151-62
ChenJH,NiRZ,XiaoMB,GuoJG,ZhouJW,,2009,Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue,Hepatobiliary Pancreat Dis Int,8,193-200
ChenR,PanS,BrentnallTA,AebersoldR,,2005,Proteomic profiling of pancreatic cancer for biomarker discovery,Mol Cell Proteomics,4,523-33
ShenJ,PersonMD,ZhuJ,AbbruzzeseJL,LiD,,2004,Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry,Cancer Res,64,9018-26
ChenJ,ChenLJ,YangRB,XiaYL,ZhouHC,WuW,,2013,Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma,Med Oncol,30,583-
CummingsJ,RaynaudF,JonesL,SugarR,DiveC,,2010,Fit-forpurpose biomarker method validation for application in clinical trials of anticancer drugs,Br J Cancer,103,1313-7
ZapataM,CohenC,SiddiquiMT,,2007,Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: Utility and potential role,Cytojournal,4,13-
GaoL,AnticT,HyjekE,GongC,MuellerJ,WaxmanI,,,Immunohistochemical analysis of E-cadherin and zeste,,,-
AliS,CohenC,LittleJV,SequeiraJH,MosunjacMB,SiddiquiMT,,2007,The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors,Diagn Cytopathol,35,644-8
DruckerE,KrapfenbauerK.,,2013,Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine,EPMA J,4,7-
GnanapragasamVJ,,2010,Unlocking the molecular archive: the emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer,BJU Int,105,274-8
FairleyJA,GilmourK,WalshK. Making,,2012,the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue,Curr Drug Targets,13,1475-87
IoannidisJP,PanagiotouOA,,2011,Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses,J Am Med Asso,305,2200-10
Taylor CR,,2006,Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology,Biotechnic Histoch,81,3-12
MatosLL,TrufelliDC,de MatosMG,,2010,Immunohistochemistry as an important tool in biomarkers detection and clinical practice,Biomark Insights,5,9-20
JambhekarNA,ChaturvediAC,MadurBP,,2008,Immunohistochemistry in surgical pathology practice: a current perspective of a simple, powerful, yet complex, tool,Indian J Pathol Microbiol,,2-11
ChangDK,JamiesonNB,JohnsAL,ScarlettCJ,PajicM,ChouA,,2013,Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater,J Clin Oncol,31,1348-56
JamiesonNB,MorranDC,MortonJP,AliA,DicksonEJ,CarterCR,,2012,MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma,Clin Cancer Res,18,534-45
WeinsteinMH,SignorettiS,LodaM.,,2002,Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells,Mod Pathol,15,1302-8
UrruticoecheaA,SmithIE,DowsettM.,,2005,Proliferation marker Ki-67 in early breast cancer,J Clin Oncol,23,7212-20
ChangF,VuC,ChandraA,MeenanJ,HerbertA,,2006,Endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic neuroendocrine tumours: cytomorphological and immunocytochemical evaluation,Cytopathology,17,10-7
GuM,GhafariS,LinF,RamzyI.,,2005,Cytological diagnosis of endocrine tumors of the pancreas by endoscopic ultrasound-guided fine-needle aspiration biopsy,Diagn Cytopathol,32,204-10
AcsG,LawtonTJ,RebbeckTR,LiVolsiVA,ZhangPJ,,2001,Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications,Am J Clin Pathol,115,85-98
JungS,WuC,EslamiZ,TanguayS,AprikianA,KassoufW,,2014,The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138,,18,27-32
BrunnstromH,JohanssonL,JirstromK,JonssonM,JonssonP,PlanckM.,,2013,Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study,Am J Clin Pathol,140,37-46
KosaracO,TakeiH,ZhaiQJ,SchwartzMR,ModyDR,,2011,S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology,Acta Cytol,55,142-8
AliA,,2015,Biomarkers for Pancreatic Cancer: Identification, Validation and Clinical application,,,-
BartlettJM,BrookesCL,RobsonT,van de VeldeCJ,BillinghamLJ,CampbellFM,,2011,Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial,J Clin Oncol,29,1531-8
HarveyJM,ClarkGM,OsborneCK,AllredDC,,1999,Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer,J Clin Oncol,17,1474-81
FuzeryAK,LevinJ,ChanMM,ChanDW,,2013,Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges,Clin Proteomics,10,13-
CuzickJ,DowsettM,PinedaS,WaleC,SalterJ,QuinnE,,2011,human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer,J Clin Oncol,29,4273-8